Atherosclerosis, a major cause of adverse cardiovascular events and mortality rates worldwide, stems from sustained lipid accumulation and subsequent chronic inflammation within the arterial walls. An early identification of patients at risk is crucial to prevent life-threatening thrombotic events and provide effective and personalized treatments. Leveraging the power of machine learning (ML) to enhance diagnostics and biomarker discovery, we applied a high-throughput approach using five ML classification algorithms (MLCA), integrating clinical and serum proteomic data from patients with carotid atherosclerotic stenosis (AT, n:60), dyslipidemic patients (DLP, n:55), and healthy controls (HC, n:66). As a result, a robust 6-protein panel (B2M, GPV, MMP9, PLF4, TSP1, and FB isoforms) was identified with a ROC-AUC value > 0.9 for all algorithms applied, highly discriminating AT patients compared to DLP or CTRL. The levels of these proteins were further validated in an independent external cohort, including patients presenting with acute atherothrombotic stroke, corroborating the potential of this panel as biomarker for atherosclerosis severity. In addition, the combined clinical-proteomic ML approach provided a more accurate patient stratification than the clinical or proteomic analysis alone. Mechanistically, the identified biomarkers highlight the importance of platelet activation, uncontrolled angiogenesis and intraplaque haemorrhage in the atherosclerotic process, underscoring the need for multipathway therapies to prevent unwanted thrombotic events.

El Instituto de Investigación e Innovación Biomédica de Cádiz participará en la organización de la Conferencia Anual de la Association of Science

Investigadores de la Universidad de Cádiz, junto al INIBICA, desarrollan STELAR

La Universidad de Cádiz ha impulsado, junto al Instituto de Investigación e Innovación Biomédica de Cádiz INiBICA, el proyecto STELAR, una

La XII convocatoria de la FCTA suma tres estancias en Charité, INIBICA y CABD para alumnos de Bachillerato de Algeciras y su comarca en 2026.

El Instituto de Investigación e Innovación Biomédica de Cádiz ha celebrado un Consejo Rector Extraordinario en el que se ha proclamado oficialmente el

Almudena Martínez valora la iniciativa y muestra la disposición para colaborar en la búsqueda de financiación